This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Rigel To Focus On Extensive Clinical Pipeline At Upcoming J.P. Morgan Presentation

Stocks in this article: RIGL

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present an update on the company's product portfolio at the J.P. Morgan Healthcare Conference in San Francisco on January 7, 2013 at 1:30pm Pacific time (see webcast details below).  In December 2012, Rigel initiated a Phase 1 clinical study of R348, a topical JAK/SYK inhibitor, as a potential therapeutic for chronic dry eye and expects to initiate a Phase 2 clinical study in mid 2013. With the addition of R348, Rigel currently has four programs in clinical development, including fostamatinib, which is completing its Phase 3 program with partner AstraZeneca.

"Rigel has created a substantial clinical portfolio with key products now in Phase 3 and Phase 2 clinical trials," said Mr. Gower. "We expect 2013 to be a transformational year for Rigel as several of these studies produce clinical results in succession."

The following is additional information about some of the programs Rigel will discuss at the J.P. Morgan Conference:

Fostamatinib Rigel's partner, AstraZeneca, reported that the Phase 3 trials of fostamatinib in the OSKIRA (Oral SYK Inhibition in Rheumatoid Arthritis) program are proceeding on course.  The program includes three pivotal studies assessing the efficacy and safety of fostamatinib in patients with rheumatoid arthritis (RA). OSKIRA-1 and OSKIRA-2 are independent 12-month studies examining the effect of fostamatinib on RA patients with inadequate responses to DMARDs, including methotrexate.  OSKIRA-3 is a 6-month study assessing the effect of fostamatinib on RA patients who have previously responded inadequately to a single anti-TNF therapy.  In addition, AstraZeneca is conducting a long-term extension study looking at the ongoing safety and tolerability of the investigational drug (OSKIRA-X).

The OSKIRA Phase 3 studies are expected to report top line results in the first half of 2013.  AstraZeneca expects to submit regulatory filings in the US and EU for fostamatinib use in combination with a DMARD, based on the OSKIRA Phase 3 program, in the second half of 2013.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,105.47 +131.16 0.77%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,537.5170 -11.7090 -0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs